Strategic funding Cour Pharma recently closed a $50 million Series B led by Lumira Ventures and Roche Venture Fund with participation from Sanofi, signaling strong investor backing and potential for strategic partnerships, co-development, and licensing opportunities to accelerate product pipelines.

Big pharma interest New investments from Sanofi and continued participation from Roche Venture Fund suggest heightened interest from large pharma in antigen-specific immune tolerance platforms, creating openings for collaboration discussions, joint development deals, and potential exit or milestone partnerships.

Clinical-stage momentum As a clinical-stage biotech with programs in PBC, T1D, MG, and celiac disease, Cour has multiple disease targets that align with high-need therapeutic areas, presenting multiple entry points for BD outreach, co-development talks, or milestone-based collaborations.

Strategic partnerships Historical partnerships with Genentech and collaborations with Takeda and Ironwood indicate a market pattern for large-company co-development, suggesting targeted outreach to identify preferred collaboration models and terms for autoimmune tolerance programs.

Operational ready A Lean company with a focused tech stack and near-term fundraising milestones, coupled with a growing executive team including a CEO and CMO appointments, implies readiness for scaled business development outreach and readiness to negotiate strategic deals, licensing, or manufacturing partnerships.